Abstract: The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I): processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular, disorders caused by the interaction of IgE with the Fc?RI receptor.

Abstract: Aspects provide for methods that successfully evaluates multiple compressional and shear arrival events received by a sonic logging tool to evaluate the presence of structures, such as shoulder beds, in downhole environments. In particular, the methods described herein enable automated determination of properties of laminated reservoir formations by, for example, enabling the automated determination of arrival times and slownesses of multiple compressional and shear arrival events received by a sonic logging tool.

Abstract: A method for annealing an absorber layer is disclosed, the method including contacting a surface of the absorber layer with an annealing material provided as a gel. The annealing material comprises cadmium chloride and a thickening agent. A viscosity of the gel of the annealing material is greater than or equal to 5 millipascal seconds.

Abstract: The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the Fc?RI receptor.

Abstract: The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the Fc?RI receptor.

Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. Anew assay for identifying compounds with this mechanism of action is also disclosed.

Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.

Abstract: A traction kite anchoring device for attachment to a harness worn by a user to transfer force from a traction kite to the user. The traction kite anchoring device comprising a first member at an end of at least one line connected to a said kite and a chicken loop for attachment to a said harness and releasably connected to said first member, wherein the chicken loop has a first end comprising an anchor able to be received and secured at an anchor receiver of the first member in a releasable and tool-less manner.

Abstract: The disclosure provides a method for producing an isoprenoid alcohol, isoprenoid alcohol derivative, or a terpene precursor thereof by microbial fermentation. Typically, the method involves culturing a recombinant bacterium in the presence of a gaseous substrate whereby the bacterium produces an isoprenoid alcohol, isoprenoid alcohol derivative, terpene or a precursor thereof. The microorganism may comprise one or more exogenous enzymes.

Abstract: A medical fluid treatment system includes a source of purified water; at least one concentrate for mixing with the water from the source to form a treatment fluid; a disposable set including a pumping portion, a concentrate line in fluid communication with the concentrate source and the pumping portion, and a patient line in fluid communication with the pumping portion, the patient line including a filter having a membrane configured to filter the treatment fluid, the filter configured such that (i) fresh treatment fluid flowing from the pumping portion towards a patient flows through the membrane and (ii) used treatment fluid flowing through the filter from the patient to the pumping portion bypasses the membrane; and a medical fluid delivery machine including a pump actuator operable with the pumping portion of the disposable set.

Abstract: The present invention relates to tetrahydrobenzo-isoquinoline sulfonamide derivatives of formula (1), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the Fc?RI receptor.

Abstract: The present invention relates to tetrahydrobenzo-isoquinoline sulfonamides derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FIERI receptor.

Abstract: A medical fluid treatment system includes a source of purified water; at least one concentrate for mixing with the water from the source to form a treatment fluid; a disposable set including a pumping portion, a concentrate line in fluid communication with the concentrate source and the pumping portion, and a patient line in fluid communication with the pumping portion, the patient line including a filter having a membrane configured to filter the treatment fluid, the filter configured such that (i) fresh treatment fluid flowing from the pumping portion towards a patient flows through the membrane and (ii) used treatment fluid flowing through the filter from the patient to the pumping portion bypasses the membrane; and a medical fluid delivery machine including a pump actuator operable with the pumping portion of the disposable set.

Abstract: Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.

Abstract: A traction kite anchor device has a base provided at an end of at least one kite line and a release member able to move relative the base by a hand of a user of the kite. A trip arm is pivotally connected to the base to move between a first rotational position relative the base and a second rotational position relative to the base. The trip arm carries a latch that can lock and release a catch of a chicken loop upon moving the release member relative the base.

Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.

Abstract: A composite stiffener for a stiffener reinforced panel is disclosed. The stiffener has a longitudinal direction and a run-out region which terminates at an end of the stiffener. The stiffener also has a constant section region inboard of the run-out region in the longitudinal direction and having a constant cross section transverse to the longitudinal direction with a crown between adjacent foot portions. The run-out region has a changing cross section transverse to the longitudinal direction with a crown between adjacent foot portions and the crown reduces in height towards the end of the stiffener forming a ramp. The composite stiffener comprises a number of blankets of non-crimp fabric layers.

Abstract: A composite stiffener for a stiffener reinforced panel is disclosed. The stiffener has a longitudinal direction and a run-out region which terminates at an end of the stiffener. The stiffener also has a constant section region inboard of the run-out region in the longitudinal direction and having a constant cross section transverse to the longitudinal direction with a crown between adjacent foot portions. The run-out region has a changing cross section transverse to the longitudinal direction with a crown between adjacent foot portions and the crown reduces in height towards the end of the stiffener forming a ramp. The composite stiffener includes a number of blankets of non-crimp fabric layers.

Abstract: An automotive air control valve comprises a housing, the housing defining an air flow path, a blade pivotally mounted within the housing, the blade pivotable between a closed position, wherein the blade substantially blocks air flow through the housing, and an open position, wherein air can flow through the housing, an actuator adapted to selectively pivot the blade between the open and closed positions, a first stop that provides a positive stop for the blade when rotated to the open position, a second stop that provides a positive stop for the blade when rotated to the closed position; and an over-center cam mechanism, wherein the over-center cam mechanism is adapted to bias the blade in the open position when the blade has been pivoted to the open position, and to bias the blade in the closed position when the blade has been pivoted to the closed position.

Abstract: The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.